Spectral domain OCT for drusen evaluation

Article

Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration

Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration from the February 2009 issue of the British Journal of Ophthalmology.

Please click here to read the full story.

Related Videos
At this year's ESCRS meeting, we asked presenters and attendees, 'What do yoou wish you'd known earlier in your ophthalmology career?'
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Related Content
Carbomer-containing gels from Aacarb, Aacomer and Puroptics could be at risk of contamination. Images courtesy of MHRA.

MHRA issues safety recall for dry eye gel treatments

November 28th 2023
Article

The carbomer-containing eye gels carry risk of microbial contamination, the regulatory agency warned

Site Logo

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023
Podcast
Rob Thornhill, CEO, Centricity Vision, at AAO 2023

AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill

November 28th 2023
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022
Podcast
Marco A. Zarbin, MD, PhD, Professor of Ophthalmology, Rutgers New Jersey Medical School

AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials

November 24th 2023
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

A physician consults a patient's chart on a clipboard. Image credit: ©tippapatt – stock.adobe.com

Disease activity criteria shapes dosing interval outcomes in clinical trials

November 22nd 2023
Article

Dr Marco Zarbin emphasises the importance of defining “active disease”

© 2023 MJH Life Sciences

All rights reserved.